135908-42-8

Basic information

• Product Name: methyl 4-carbamoylbicyclo[2.2.2]octane-1-carboxylate
• Synonyms: methyl 4-carbamoylbicyclo[2.2.2]octane-1-carboxylate
• CAS NO: 135908-42-8
• Molecular Formula: C11H17NO3
• Molecular Weight: 211.25758
• Mol File: 135908-42-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 356.0±41.0 °C(Predicted)
• Appearance: /
• Density: 1.253±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 16.66±0.40(Predicted)
• CAS DataBase Reference: methyl 4-carbamoylbicyclo[2.2.2]octane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-carbamoylbicyclo[2.2.2]octane-1-carboxylate(135908-42-8)
• EPA Substance Registry System: methyl 4-carbamoylbicyclo[2.2.2]octane-1-carboxylate(135908-42-8)

Safety Data

• Hazardous Substances Data: 135908-42-8(Hazardous Substances Data)

Upstream product

• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 

Downstream Products

• 54202-05-0 methyl 4-cyanobicyclo[2.2.2]octane-1-carboxylate 

Relevant articles and documents

COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF

A compound of formula (I), a preparation method therefor, a pharmaceutical composition containing a derivative thereof, and the therapeutic uses thereof, especially inhibiting PGE2/EP4 signalling transduction and the uses thereof for treating cancer, acute or chronic pain, migraine, osteoarthritis, rheumatoid arthritis, gout, bursitis, ankylosing spondylitis, primary dysmenorrhea, tumour or arteriosclerosis.

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R2, R3a, R3b, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.